Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
HAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) —
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its Bentrio nasal spray will be re-launched in Europe, initially in Germany, beginning in early October of 2022.
Related news for (CYTO)
- Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
- Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
- altamira therapeutics provides update on nasdaq listing
- altamira therapeutics announces extended iso 13485 quality management system certification for bentrio nasal spray
- altamira therapeutics provides business update and first half 2024 financial results